GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Net Income (Continuing Operations)

Progen Co (XKRX:296160) Net Income (Continuing Operations) : ₩-5,654.5 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Progen Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Progen Co's Net Income (Continuing Operations) for the six months ended in Dec. 2024 was ₩-5,654.5 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-5,654.5 Mil.

Progen Co Net Income (Continuing Operations) Historical Data

The historical data trend for Progen Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Net Income (Continuing Operations) Chart

Progen Co Annual Data
Trend Dec23 Dec24
Net Income (Continuing Operations)
8,964.94 -5,654.49

Progen Co Semi-Annual Data
Dec23 Dec24
Net Income (Continuing Operations) 8,964.94 -5,654.49

Progen Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-5,654.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Progen Co  (XKRX:296160) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Progen Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Progen Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Progen Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Net Income (Continuing Operations)
Comparable Companies
XKRX:049960 XKRX:261780 XKRX:166480 XKRX:388870 XKRX:378800 XKRX:314130 XKRX:348150 XKRX:067370 XKRX:168330 XKRX:185490 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR
Website
http://www.progen.co.kr
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines